Drug Trial Radar · NCT01076010
An Extension Treatment Protocol for Subjects Who Have Participated in a Study of Tivozanib Versus Sorafenib in Kidney Carcinoma (Protocol AV-951-09-301).
Last checked: Nov 19, 2026Latest source record: Oct 5, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
277
Actual
Start
Mar 2010
Primary completion
Jul 2014
Study completion Jul 2014
Sponsor
- Lead sponsor
- AVEO Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Feb 25, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Open-label, multi-center extension treatment protocol to allow access to tivozanib and sorafenib for subjects who have participated on the AV-951-09-301 protocol. Eligible subjects who were randomized to receive sorafenib on AV-951-09-301 and had documented progression of disease will receive a tivozanib dose of 1.5 mg/day. Eligible subjects who were randomized to tivozanib or sorafenib in AV-951-09-301, and displayed clinical benefit and acceptable tolerability to treatment, will continue to receive tivozanib or sorafenib at the same dose and schedule as in AV-951-09-301.
Conditions
- Advanced Renal Cell Carcinoma
Interventions
TivozanibDrug
Tivozanib capsules, administered orally, on a dosing schedule of 3 weeks of treatment (beginning on Day 1) followed by 1 week off treatment. One cycle was defined as 4 weeks of treatment.
SorafenibDrug
Sorafenib tablets, 400 mg twice daily, administered orally for 4 weeks (1 cycle = 4 weeks). One cycle was defined as 4 weeks of treatment. Cycles were repeated every 4 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Days Subjects Received Treatment in Each Treatment ArmTime frame: From enrollment to until all subjects discontinue (due to documented progressive disease [PD] or unacceptable toxicities) or until 3 years after the first subject was enrolled in Protocol AV-951-09-902
- Number of Cycles Subjects Received Treatment in Each Treatment ArmTime frame: From enrollment to until all subjects discontinue (due to documented PD or unacceptable toxicities) or until 3 years after the first subject was enrolled in Protocol AV-951-09-902
- Total Dose Administered to Subjects in Each Treatment Arm (mg)Time frame: From enrollment to until all subjects discontinue (due to documented PD or unacceptable toxicities) or until 3 years after the first subject was enrolled in Protocol AV-951-09-902
- Average Daily Dose Administered to Subjects in Each Treatment ArmTime frame: From enrollment to until all subjects discontinue (due to documented PD or unacceptable toxicities) or until 3 years after the first subject was enrolled in Protocol AV-951-09-902
- Relative Dose Intensity (RDI) of Treatment Administered to Subjects in Each Treatment ArmTime frame: From enrollment to until all subjects discontinue (due to documented PD or unacceptable toxicities) or until 3 years after the first subject was enrolled in Protocol AV-951-09-902
- Number of Subjects With Adverse EventsTime frame: From enrollment assessed up to 3 years of treatment or until follow-up (up to 30 days end-of-trial visit after treatment discontinuation), whichever occurs earlier
Locations
75 sites in 15 countries. Site status is shown where the registry gives one.
Site 185
Los Angeles, California
Site 184
Orlando, Florida
Site 182
Minneapolis, Minnesota
Site 186
New York, New York
Site 187
Dallas, Texas
Site 403
Plovdiv, Bulgaria
Site 404
Sofia, Bulgaria
Site 400
Sofia, Bulgaria
Site 401
Varna, Bulgaria
Site 402
Veliko Tarnovo, Bulgaria
Site 110
Montreal, Quebec, Canada
Site 122
Santiago, Chile
Site 123
Temuco, Chile
Site 411
Prague, Czechia
Site 133
Saint-Herblain, France
Site 423
Budapest, Hungary
Site 421
Kaposvár, Hungary
Site 422
Pécs, Hungary
Site 154
Delhi, India
Site 156
Ahmedabad, Gujarat, India
Site 151
Nashik, Maharashtra, India
Site 153
Pune, Maharashtra, India
Site 191
Jaipur, Rajasthan, India
Site 152
Vellore, Tamil Nadu, India
Site 158
Lucknow, Uttar Pradesh, India
Site 150
Kolkata, West Bengal, India
Site 160
Arezzo, Italy
Site 161
Pavia, Italy
Site 162
Roma, Italy
Site 432
Bialystok, Poland
Site 434
Bydgoszcz, Poland
Site 431
Gdansk, Poland
Site 435
Olsztyn, Poland
Site 433
Poznan, Poland
Site 430
Warsaw, Poland
Site 436
Warsaw, Poland
Site 444
Brasov, Romania
Site 441
Bucharest, Romania
Site 440
Bucharest, Romania
Site 443
Bucharest, Romania
Showing 40 of 75 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.